There's money in looking and feeling good, and Wall Street has caught on the trend.
Image by Peshkova at Adobe Stock
Weight loss has taken center stage on Wall Street, after the mega successes of Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro. In 2023, Ozempic and obesity formulation Wegovy, generated a whopping $18.4 billion for Novo Nordisk, or over half of the company’s total revenue. Eli Lilly’s newer drugs Mounjaro and Zepbound brought in $5.2 billion in total. Wall Street analysts are projecting even greater sales from these weight loss treatments in 2024, which is drawing investor interest to the aesthetics and weight loss market.
